Cyxone AB Logo

Cyxone AB

A clinical-stage biotech developing therapies for autoimmune and autoinflammatory diseases.

CYXO | ST

Overview

Corporate Details

ISIN(s):
SE0007815428 (+2 more)
LEI:
54930034OH16ROAY4K87
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö

Description

Cyxone AB is a clinical-stage biotechnology company focused on developing disease-modifying therapies for autoimmune and autoinflammatory diseases. The company's portfolio includes two primary drug candidates in clinical development. Rabeximod is an immunomodulating agent being investigated for the treatment of rheumatoid arthritis. T20K is a drug candidate for multiple sclerosis, developed using the company's cyclotide technology platform, which is based on stable, plant-derived peptides. Cyxone aims to develop therapies that can significantly improve the quality of life for patients with these chronic conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cyxone AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cyxone AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cyxone AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-28 Carl Magnus Högerkorp Other Buy 64,950 40,788.60 SEK
2023-06-27 Carl Magnus Högerkorp Other Buy 6,050 3,690.50 SEK
2023-03-03 Carl Magnus Högerkorp Other Buy 100,010 51,005.10 SEK
2023-03-02 Carl Magnus Högerkorp Other Buy 10,873 5,653.96 SEK
2021-07-15 Bert Junno Other Other 1,788,732 7,763,096.88 SEK
2021-07-15 Bert Junno Other Other 1,788,732 N/A
2021-07-14 Bert Junno Other Other 1,788,786 7,790,163.03 SEK
2021-07-14 Bert Junno Other Other 1,788,786 N/A
2021-07-12 Mikeoo Holding AB Other Other 1,788,732 7,441,125.12 SEK
2021-07-12 Mikael Lindstam Other Other 1,788,732 N/A

Peer Companies

Evotec SE Logo
A life science company offering drug discovery and development partnership solutions.
Germany
EVT
EXICURE, INC. Logo
Early-stage biotech developing nucleic acid therapies based on SNA technology.
United States of America
XCUR
EyeGene,Inc Logo
Develops gene/cell therapies for age-related diseases and preventive vaccines.
South Korea
185490
Femtobiomed Inc. Logo
Develops a non-viral intracellular delivery platform for cell and gene therapy.
South Korea
327610
Develops AI data center campuses with co-located hybrid power generation.
United States of America
FRMI
Fluicell AB Logo
A biotech firm creating engineered tissues for regenerative medicine and drug development.
Sweden
FLUI
Foghorn Therapeutics Inc. Logo
Develops medicines targeting the chromatin regulatory system for oncology.
United States of America
FHTX
Fortrea Holdings Inc. Logo
A global CRO providing clinical development and patient access solutions to life sciences.
United States of America
FTRE
FUSION ANTIBODIES PLC Logo
CRO providing end-to-end services for preclinical antibody development.
United Kingdom
FAB
Genenta Science S.p.A. Logo
Clinical-stage developer of hematopoietic stem cell gene therapies for immuno-oncology.
United States of America
GNTA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.